← Projects
P / 02NMN · NAD+ Precursor CapsulesBiotech

Enzymatic NMN at scale — manufactured in Australia.

Commercial · Live · Made in Australia

Natural Biotech Pty Ltd's flagship NMN (β-Nicotinamide Mononucleotide) capsule line is manufactured in South Australia under a contracted research relationship with the University of Adelaide. NMN is a direct precursor to NAD+, a coenzyme central to cellular energy metabolism whose levels decline with age.

The programme is built around an enzyme-catalysed synthesis pathway designed for purity, cost-efficient scale-up and a globally distributable supplement format — manufactured in Australia and distributed internationally.

Key activities

  • Enzyme-catalysed NMN synthesis optimised for purity and yield.
  • Australian manufacturing and quality control to supplement-grade standards.
  • Contracted research relationship with the University of Adelaide.
  • Global distribution of a 12,000 mg capsule format.

Outcomes & targets

  • Commercial, live product line manufactured in Australia.
  • Cost-efficient, scalable enzymatic process.
  • Globally distributable format addressing age-linked NAD+ decline.

Industry context

The longevity and healthy-ageing supplement category has grown rapidly, with NAD+ precursors among the most studied compounds. Reliable, high-purity, cost-effective manufacturing — and the institutional capacity to scale it — is the differentiator between a research molecule and a distributable product.

Partners

Commercial · LiveMade in AustraliaUniversity of AdelaideNatural Biotech Pty Ltd